title: [HER2-positive breast cancer: standard and double targeted therapy].
abstract: Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin) and pertuzumab significantly improves outcomes in HER2-positive breast cancer patients. A certain part of HER2-positive patients can be cured by using only targeted drugs without chemotherapy.
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
authors.forename: A A
authors.initials: AA
authors.lastname: Bozhok
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Semiglazova
authors.forename: A G
authors.initials: AG
authors.lastname: Vasil'ev
authors.forename: A G
authors.initials: AG
authors.lastname: Manikhas
authors.forename: V V
authors.initials: VV
authors.lastname: Semiglazov
authors.forename: A A
authors.initials: AA
authors.lastname: Bessonov
authors.forename: K S
authors.initials: KS
authors.lastname: Nikolaev
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000188:drug therapy; D000077341:Lapatinib; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D020360:Neoadjuvant Therapy / Q000379:methods*; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab